Novartis ESMO Event Presentation

Other than Pluvicto crossover and concurrent radiation, no major difference in post-progression therapies between treatments arms Antineoplastic therapy since discontinuation of study drug by medication type¹ Medication Type Pluvicto as crossover treatment 177Lu-PSMA-617 N=234 | n (%) ARPI N=234 | n (%) 0 123 (84.2) 36 (15.4) 66 (28.2) Radiation therapy Concurrent (includes crossover treatment) 7 (3.0) 39 (16.7) Post-study treatment 29 (12.4) 27 (11.5) ≥ 1 subsequent ANP medication (excluding crossover) 81 (34.6) 68 (29.1) 70 (29.9) 61 (26.1) Chemotherapy 13 (5.6) 4 (1.7) Hormonal therapy 5 (2.1) 2 (0.9) Biologic therapy Targeted therapy (excluding radioligand therapy) 2 (0.9) 3 (1.3) PSMA-directed radioligand therapy 1 (0.4) 5 (2.1) 1 (0.4) 0 Other 1. Full analysis set. A medication/therapy can appear with more than one medication type. Only ANP medications that started after the end of randomized treatment date are summarized. For crossover subjects all antineoplastic medications after crossover are included in the ARPI column. Targeted therapies reported: capivasertib, olaparib, and NUV-868 (BETI). PSMA-directed radioligand therapies reported: Pluvicto, 67CuBIPSMA. 23 NOVARTIS ESMO EVENT | OCTOBER 24, 2023 | INVESTOR PRESENTATION NOVARTIS | Reimagining Medicine

View entire presentation